Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor

Portfolio > Investment VIPs

Zurich Unit Turns Prescription Drug Royalties Into Collateral

X
Your article was successfully shared with the contacts you provided.

NU Online News Service, Aug. 10, 1:56 p.m. – The Centre Group, Hamilton, Bermuda, an arm of Zurich Financial Services Group, says it has used an unusual investment strategy to help Royalty Pharma A.G. Schaffhausen, Switzerland, a pharmaceutical company, get $60 million in loans.

Centre helped Royalty Pharma get the financing by turning the expected royalty streams from a portfolio of nine prescription drugs that are already on the market, and another drug that is still in development, into collateral.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.